Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL881749 | 0.79 | STAT3 (0.77) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL881769 | 0.78 | MEN1 (0.76) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL27713666 | 0.77 | FFAR2 (0.71) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5836187 | 0.76 | CDK2 (0.67) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL18529275 | 0.74 | ATG4B (1.00) | ATG4BCDK2 | |
| Nithiamide SCHEMBL158858 | 0.73 | NPC1 (0.63) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25063115 | 0.73 | STAT3 (0.67) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29056971 | 0.73 | MEN1 (0.52) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL12974224 | 0.71 | STAT3 (0.75) | ATG4BMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25063151 | 0.71 | STAT3 (0.64) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825637-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | Children's Medical Center Corporation (US) | 2015-01-21 | — | — | EP | claimed |
| WO-2013138623-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-09-19 | — | — | WO | claimed |
| US-20060194854-A1 | New 2-substituted - 1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | claimed |
| US-20050119321-A1 | 2-substituted-1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | claimed |
| EP-1499601-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003089419-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | claimed |
| US-20180112182-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-04-26 | — | — | US | disclosed |
| US-9771560-B2 | High-throughput image-based chemical screening in zebrafish blastomere cell culture | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20150147807-A1 | HIGH-THROUGHPUT IMAGE-BASED CHEMICAL SCREENING IN ZEBRAFISH BLASTOMERE CELL CULTURE | HOWARD HUGHES MEDICAL INSTITUTE | 2015-05-28 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20060194854-A1 | New 2-substituted - 1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | disclosed |
| US-20050119321-A1 | 2-substituted-1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1499601-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003089419-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | ATG4B 2074/4885MEN1 3062/4885KMT2A 2164/4885 |
| US-20060194854-A1 | New 2-substituted - 1,3-thiazole compounds | NR3C2, NR4A2, NR0B1 | ATG4B 3617/4885MEN1 2756/4885KMT2A 4047/4885 |
| US-20050119321-A1 | 2-substituted-1,3-thiazole compounds | NR3C2, NR4A2, NR4A3 | ATG4B 3788/4885MEN1 2053/4885KMT2A 3948/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | ATG4B 1474/4885MEN1 3882/4885KMT2A 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.